Project: A novel therapeutic antibody and companion diagnostic for non-ischaemic cardiac remodelling
NOVA-CARE aims to establish preclinical efficacy in mouse and porcine disease models for a novel therapeutic monoclonal antibody (mAb) to prevent non-ischaemic heart failure (NI-HF) by targeting EDA-fibronectin (EDA). This protein is upregulated during adverse cardiac remodelling, which leads to heart failure (HF). In addition, a companion diagnostic will be developed using biomarkers linked to EDA expression, to identify patients at risk for developing NI-HF, and to optimize mAb treatment.
Acronym | NOVA-CARE (Reference Number: 10421) |
Duration | 01/10/2016 - 01/10/2019 |
Project Topic | Biological Sciences / Technologies |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 5 |